EP4200285A1 - Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires - Google Patents

Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires

Info

Publication number
EP4200285A1
EP4200285A1 EP21762623.3A EP21762623A EP4200285A1 EP 4200285 A1 EP4200285 A1 EP 4200285A1 EP 21762623 A EP21762623 A EP 21762623A EP 4200285 A1 EP4200285 A1 EP 4200285A1
Authority
EP
European Patent Office
Prior art keywords
skin
connection
cosmetic
isobutyramides
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21762623.3A
Other languages
German (de)
English (en)
Inventor
Ludger Kolbe
Jörn Hendrik Reuter
Ahmed Kamal
Judith SEIDEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP4200285A1 publication Critical patent/EP4200285A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin

Definitions

  • the present invention relates in particular to N-(4-(2,4-dihydroxy- 3-methylphenyl) thiazole-2-yl) isobutyramide and hydroxy-methoxy-phenylthiazole isobutyramide, but also their derivatives, cosmetic and / or dermatological preparations containing them, and their use for the prophylaxis and treatment of sensitive, in particular inflamed skin or inflammatory skin conditions in human skin. Changes associated with the aging process, but also other intrinsic and extrinsic factors (e.g.
  • skin irritation is to be understood as meaning any change in the skin that triggers sensory discomfort in humans or animals and/or is characterized by a dry, reddened and/or inflamed complexion.
  • sensory discomfort also includes conditions such as itching or pain.
  • skin irritation can include phenomenologically different skin conditions: Sensitive skin, sensitive skin including a sensitive scalp, vulnerable skin, dry skin, atopic and psoriatic skin, irritated skin, rosacea, inflamed skin, and skin changes in diabetes mellitus, which in each case have a higher degree of severity in a skin reddening, the so-called erythema.
  • Sensitive skin sensitive skin including a sensitive scalp, vulnerable skin, dry skin, atopic and psoriatic skin, irritated skin, rosacea, inflamed skin, and skin changes in diabetes mellitus, which in each case have a higher degree of severity in a skin reddening, the so-called erythema.
  • the problem of "sensitive skin” affects a growing number of adults and children. It is now assumed that up to 50% of the population has sensitive skin (L. Misery et al., Ann. Dermatol. Venereol.2005, 132, 425-4
  • Typical disturbing phenomena associated with the terms "stinging” or “sensitive skin” are skin reddening, tingling, tingling, tightening and burning of the skin and itching. They can be caused by stimulating environmental conditions such as B. massage, surfactants, exposure to other chemical substances such. B. lactic acid, weather influences such as heat, cold, drought, but also damp heat, thermal radiation and UV radiation, z. B. the sun, or psychological stress.
  • “Sensitive” scalps are also characterized by skin redness, tingling, tingling, burning and itching. Triggers are, for example, soap, shampoo or other hair care products, surfactants, hard water with a high concentration of lime and/or mechanical stress. Erythema and hyperseborrhoea (excessive production of sebum) of the scalp and dandruff are often associated with the phenomena described.
  • Atopy a familial hypersensitivity of the skin and mucous membranes to environmental substances, with an increased willingness to react to substances from the natural environment. to develop. Atopy is thought to be genetic. Atopy can manifest itself as atopic dermatitis. The skin barrier is damaged, the skin is often inflamed and itchy.
  • the erythematous effect of the ultraviolet part of solar radiation or artificial radiation on the skin is well known. While rays with a wavelength shorter than 290 nm (the so-called UVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more or less severe burns. Erythematous skin manifestations also occur as side effects of certain skin diseases or irregularities, for example acne, bacterially induced skin inflammation, cutaneous reactions, dermographism, skin soreness in general, skin moles, erysipelas, shingles, frostbite or burns.
  • certain skin diseases or irregularities for example acne, bacterially induced skin inflammation, cutaneous reactions, dermographism, skin soreness in general, skin moles, erysipelas, shingles, frostbite or burns.
  • Rosacea is a special form of reddening of the skin. Anti-inflammatory preparations can therefore also are used to advantage in general, disease-related reddening of the skin and in particular rosacea to subside, to suppress them over a longer period of time and to largely prevent their recurrence.
  • Anti-inflammatory agents can therefore also help to reduce the consequences of an insect bite, such as reddening, wheal formation, itching and painful swelling of the skin, suppress them over a longer period of time and prevent them from reoccurring.
  • Erythemas also occur more frequently in the diaper area of small children, all the more so in infants (diaper dematitis). Incontinence, a condition that occurs more frequently in older people, is often associated with erythema and reddening of the skin as a result of constant exposure to moisture and irritants (incontinence dermatitis).
  • the substances used in cosmetic and/or pharmaceutical products are - toxicologically harmless, - well tolerated by the skin, - stable (in particular in conventional cosmetic and/or pharmaceutical formulations), - preferably faintly odorous or (largely) odorless, - preferably colorless and non-discolouring, and - be inexpensive to produce (ie using standard processes and/or starting from standard precursors).
  • an anti-inflammatory active ingredient which preferably fulfills one or more of the aforementioned secondary conditions and particularly preferably all of the aforementioned conditions.
  • the present invention relates to the use of topical preparations for removing sebum from the skin, in particular for removing and clearing comedones, for preventing the formation of comedones, for the prophylaxis and treatment of mild forms of acne and for the prophylaxis and control of seborrhea.
  • Sebum is the secretion of the sebaceous gland. Sebaceous glands are bulges in the follicular epithelium and are therefore part of the follicle, with which they form a functional unit. They are holocrine glands, which means that most of the gland cell is converted into the secretion sebum. The cells of the sebaceous gland, which are constantly renewed from below, become fatty and disintegrate, and the skin sebum thus formed is emptied through the follicle openings onto the skin's surface.
  • the sebum consists of mono -, di- and triglycerides (C 10 -C 18 ), waxes (C 16 -C 26 ), wax esters (C 28 -C 38 ), normal saturated fatty acids (C 10 -C 18 ), branched chain saturated fatty acids (C 11 - C 18 ), polybranched saturated fatty acids (C 13 -C 18 ), monounsaturated fatty acids (C 11 - C 18 ), polyunsaturated fatty acids (C 13 , C 15 -C 17 ), sterols (cholesterol, 7-dehydrocholesterol, 7-hydroxycholesterol), branched and unbranched hydrocarbons (C 30 -C 40 ), squalene and phospholipid
  • the lipids of the sebaceous glands form the so-called hydro-lipid film of the skin.
  • This surface film is an emulsion, which can be a water-in-oil or an oil-in-water emulsion. It has the function of keeping the skin's surface supple and regulating the water content of the deeper skin layers.
  • the sebum When the sebum is well hydrated, the water content is at least 10 to 20% by weight and the sebum is hydrophilic. If the hydrophilic-lipophilic balance of the surface film is no longer given and the water content falls, the sebum changes and becomes hydrophobic. The flow of sebum from the sebaceous gland and follicle is impeded. The sebum accumulates in the follicle openings, which can then lead to comedones and inflammation of the follicles.
  • comedones can have various causes. For example: external influences such as incorrect cleaning habits and incorrect care, comedogenic substances in cosmetics, weather influences, alkaline soaps, harsh detergents. Increased sebum secretion and the formation of comedones can also develop as a result of genetic factors and hormonal influences. Here, too, comedones, inflammation, pre-acne and acne with their after-effects can be the result.
  • soaps have the disadvantage that the water-insoluble calcium and magnesium salts of the higher fatty acids that form when the soaps are used in hard water form slimy deposits on the skin. If it is difficult to rinse off, these deposits remain on the skin longer, clog the follicle openings and can lead to the formation of comedones. For this reason, syndets (i.e. non-soap tensides) in the form of cleansing creams or cleansing lotions are predominantly used for skin cleansing. Although these syndets do not form lime soaps, treatment with highly surface-active agents has a stronger degreasing and drying effect on the skin than soap.
  • Seborrhea is a predisposition to increased function of the sebaceous glands. Both scalp and facial skin appear greasy. The composition of seborrhoeic sebum is different from that of normal sebum. There are 3 stages of seborrhoea development:
  • the excessive secretion of the sebaceous glands can be triggered, among other things, by androgenetic disorders and has an aesthetic disadvantage on the overall appearance of the hair. This disorder can also be the cause of hair loss that occurs.
  • the precursor to each is the seborrhoeic condition of the scalp. Vegetative disorders and improper care can worsen the complexion and hair condition. Even with seborrhea, the hair itself can be dry due to disturbances in the keratin structure. Dry, damaged hair is often caused by external stress such. B. sun or chemical treatments. Blow-drying that is too hot or not properly caring for damaged hair can lead to damage.
  • Greasy hair has very annoying effects.
  • the hair becomes stringy again a short time after washing and the hairstyle does not last.
  • Greasy hair and dandruff are among the most common hair problems. These anomalies are due to a disturbance in the activity of the sebaceous glands. If the sebaceous glands are overactive, we speak of seborrhea. There are two forms to be distinguished: the oily form (seborrhea oleosa) and the dry form (seborrhea sicca).
  • the treatment of seborrhea includes, first of all, regular and thorough washing of the head with special shampoos, which can be carried out as often as seems necessary.
  • the wash should be combined with a massage in the connective tissue, because this empties the sebaceous glands more, which delays the subsequent greasing.
  • the object of the present invention is to provide a preparation that does not have the disadvantages of the known and previously used agents, which simultaneously has a sebum-dissolving, fat-regulating and caring effect, removes existing comedones without irritation, and degreases and dehydrates the skin effectively prevents the formation of comedones and the development of acne cosmetics, as well as improves existing acne and cares for the skin in the same way.
  • Isobutyramides of the general formula where n: means that 1 to 5 identical and/or different substituents R 1 are present can, where the single or multiple substituents R 1 : independently of one another can mean: OH, CH 3 , O-CH 3 , O- (CO) -CH 3 (acetyl), wherein
  • R 2 H or a C 1 - C 4 - alkyl chain
  • R 3 can be H or CH 3 but excludes the isobutyramide of the structure.
  • the isobutyramides according to the invention are excellent active ingredients for the prophylaxis and treatment of sensitive skin, itching and inflammatory phenomena in human skin.
  • the active ingredients used according to the invention prevent the formation of seborrheic phenomena, particularly greasy hair but also dandruff, and eliminate existing seborrheic phenomena, particularly greasy hair but also dandruff.
  • the present invention ensures very good skin care, combined with efficient removal of excess skin sebum.
  • a method for combating impure skin, acne, or seborrheic phenomena, in particular greasy hair and/or dandruff is characterized in that the active ingredients used according to the invention are in a suitable cosmetic or dermatological vehicle with which the increased sebum production is affected Area to be contacted.
  • the prior art did not provide the slightest indication of the use according to the invention as an antiseborrheic principle of action.
  • a further preferred embodiment of the present invention are therefore formulations to be used against dandruff, for example anti-dandruff shampoos.
  • EP 3 176 156 A1 describes similar isobutyramides, but the substances according to the invention are not specifically disclosed in this document.
  • EP 3 176 156 A1 is the reduction in skin pigmentation.
  • this effect does not occur with the (here) isobutyramides according to the invention and would also be undesirable according to the invention.
  • Cosmetic or dermatological preparations according to the invention preferably contain 0.000001 to 10% by weight, particularly preferably 0.0001 to 3% by weight and very particularly preferably 0.001 to 1% by weight of isobutyramides, based on the total weight of the preparations.
  • connection 1 isobutyramides for the purposes of the present invention.
  • connection 9 connection 10
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of the active ingredient used according to the invention takes place in the usual way, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be present in various forms. So you can e.g. a solution, an emulsion of the water-in-oil (W/O) or oil-in-water (O/W) type, or a multiple emulsion, for example of the water-in-oil-in-water type (W/O/W) or oil-in-water-in-oil (O/W/O), a hydrodispersion or lipodispersion, a Pickering emulsion, a gel, a solid stick or an aerosol.
  • W/O water-in-oil
  • O/W oil-in-water
  • a hydrodispersion or lipodispersion for example of the water-in-oil-in-water type (W/O/W) or oil-in-water-in-oil (O/W/O)
  • a hydrodispersion or lipodispersion for example of the water
  • Emulsions according to the invention for the purposes of the present invention are advantageous and contain z.
  • auxiliaries and additives include, for example, consistency enhancers, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, sunscreens, stabilizers, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytic substances, etc.
  • Medicinal topical compositions within the meaning of the present invention usually contain one or more medicaments in an effective concentration.
  • cosmetic or topical dermatological compositions according to the present invention can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nourishing cream, day or night cream, etc. It is optionally possible and advantageous to use the compositions according to the invention as a basis to use for pharmaceutical formulations.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin and/or the hair in sufficient amounts in the manner customary for cosmetics. upset by the crowd.
  • sunscreen preparations which are in the form of a sunscreen are particularly preferred.
  • these can additionally contain at least one further UVA filter and/or at least one further UVB filter and/or at least one inorganic pigment, preferably an inorganic micropigment.
  • the cosmetic and dermatological preparations can contain cosmetic auxiliaries of the type customarily used in such preparations, eg preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing agents and/or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries of the type customarily used in such preparations, eg preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing agents and/or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • An additional content of customary antioxidants is generally preferred. According to the invention, all antioxidants that are suitable or customary for cosmetic and/or dermatological applications can be used as favorable antioxidants.
  • the amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 -
  • the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fatty substances preferably esters of fatty alcohols with alcohols with a low carbon number, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low carbon number or with fatty acids;
  • Alcohols, diols or polyols with a low carbon number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
  • mixtures of the aforementioned solvents are used.
  • water can also be an additional component.
  • the cosmetic or dermatological preparation according to the present invention is a solution or emulsion or dispersion
  • the following solvents can be used: water or aqueous solutions oils such as triglycerides of capric or caprylic acid, but preferably castor oil; - fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty alcohols with alcohols with a low carbon number, e.g.
  • mixtures of the aforementioned solvents are used.
  • water can also be an additional component.
  • suitable propellants for cosmetic and/or dermatological preparations that can be sprayed from aerosol containers are the customary, readily volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or mixed with one another. Compressed air is also advantageous to use.
  • Cosmetic preparations within the meaning of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents customarily used for this purpose, preferably water, also organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, Hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose or inorganic thickeners, e.g. B. aluminum miniumsilicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • the thickening agent is contained in the gel, for example, in an amount of between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • the light protection formulations can advantageously contain further substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, is in particular 1 to 6% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
  • Leukotrienes which also promote inflammation, can also be formed from arachidonic acid in the skin by migrating neutrophilic granulocytes. Therefore, a reduction in leukotrienes, especially LTB 4 , is recommended for efficient effectiveness.
  • Figure 2 demonstrates the reduction of Ca ionophore-stimulated LTB 4
  • Granulocytes are the first immune cells to migrate into the skin after an inflammatory stimulus. Although the "oxidative burst" of the granulocytes is very important for the defense against infection, an excessive burst in the tissue can cause major collateral damage. In the case of severe inflammation, it may therefore be advisable to dampen this reaction with anti-inflammatory substances.
  • Fig. 3 demonstrates the reduction of the "oxidative burst" of fMLP-stimulated neutrophils
  • step 03 Compound 2: N-(4-(2,4-bis(methoxy)phenyl)thiazol-2-yl)isobutyramide Step 01 step 02 step 03 Connections 12 and 13 step 01 step 02 or

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

Nouveaux isobutyramides.
EP21762623.3A 2020-08-19 2021-08-02 Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires Pending EP4200285A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102020210535.9A DE102020210535A1 (de) 2020-08-19 2020-08-19 Neue Isobutyramidderivate, kosmetische und/oder dermatologischen Zubereitungen, solche Verbindungen enthaltend, sowie deren Verwendung zur Prophylaxe vor und Behandlung von sensibler, insbesondere entzündeter Haut bzw. entzündlichen Hautzuständen
PCT/EP2021/071523 WO2022037927A1 (fr) 2020-08-19 2021-08-02 Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires

Publications (1)

Publication Number Publication Date
EP4200285A1 true EP4200285A1 (fr) 2023-06-28

Family

ID=77543471

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21762623.3A Pending EP4200285A1 (fr) 2020-08-19 2021-08-02 Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires

Country Status (6)

Country Link
US (1) US20230312495A1 (fr)
EP (1) EP4200285A1 (fr)
CN (1) CN116096346A (fr)
BR (1) BR112023003093A2 (fr)
DE (1) DE102020210535A1 (fr)
WO (1) WO2022037927A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554122B (zh) * 2023-06-29 2023-09-19 南京桦冠生物技术有限公司 α-酮酸酰胺或取代草酸酰胺酯类化合物及其组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011083259A1 (de) 2011-09-23 2013-03-28 Beiersdorf Ag Alkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Alkylamidothiazolen
DE102013226711A1 (de) 2013-12-19 2015-06-25 Beiersdorf Ag Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut

Also Published As

Publication number Publication date
US20230312495A1 (en) 2023-10-05
BR112023003093A2 (pt) 2023-03-28
WO2022037927A1 (fr) 2022-02-24
DE102020210535A1 (de) 2022-03-24
CN116096346A (zh) 2023-05-09

Similar Documents

Publication Publication Date Title
DE60313597T2 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
EP0847279B1 (fr) Compositions cosmetiques et/ou pharmaceutiques antiprurigineuses contenant un ou plusieurs anesthesiques locaux legers et un ou plusieurs astringents
EP3082752B1 (fr) Utilisation d'alkylamidothiazoles dans des préparations cosmétiques ou dermatologiques pour assurer la prophylaxie et le traitement des peaux sensibles
EP0687467A2 (fr) Préparations cosmétiques et dermatologiques contenant des éthers de glycerylalkyl comme composant actif
DE69916695T2 (de) Verwendung mindestens eines Hydroxystilben als Mittel zur Verringerung der Adhäsion von Mikroorganismen
EP0596284A2 (fr) Compositions cosmétiques et dermatologiques antimycosiques contenant des esters d'acides gras
EP1172084A2 (fr) Composition cosmétique et dermatologique pour éliminer du sébum
DE10025124B4 (de) Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
EP1179338A1 (fr) Compositions cosmétiques et dermatologiques comprenant des cyclodextrines pour enlever le sebum
EP4200285A1 (fr) Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires
DE19615575A1 (de) Verwendung von Glucosiden und Ferulasäure als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
DE102005008299A1 (de) Universalpflegecreme
EP2711050A1 (fr) Composition et préparation cosmétique comprenant une telle composition
WO2009115216A1 (fr) Utilisation d'un constituant ou d'un extrait de baobab en cas de maladies de peau
WO2005030157A1 (fr) Preparations cosmetiques ou dermatologiques a teneur en isoflavones et en licochalcone a
EP1377254A2 (fr) Preparations cosmetiques et dermatologiques contenant des isoflavones
EP2560666A1 (fr) Combinaisons de principes actifs d'extrait d'écorce de magnolia et d'agents tensioactifs (polyglycéryl (3)-méthylglucosedistéarate)
EP1834631B1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et des dérivés de glucose ou des ethers de glycérine
EP0620000A3 (fr) Utilisation cosmétique et/ou pharmaceutique des N-acylalcanolamines
EP1383473A2 (fr) Preparations cosmetiques et dermatologiques renfermant un extrait de houblon ou de houblon-malt et leur utilisation pour la reduction de la secretion de sebum cutane
DE19615578A1 (de) Verwendung von Salix nigra-Extrakt als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
EP2076240B1 (fr) Préparations cosmétiques ou dermatologiques comprenant de l'ester méthylique de la 2-isopropyl-5- méthyl-cyclohexanecarbonyl-d-alanine et une ou plusieurs substances actives anti-inflammatoires
DE19832889A1 (de) Verfahren zur Isolierung und Reinigung von Fettsäuren und Hydroxyfettsäuren aus Insektenwachsen und deren Verwendung
WO2023151898A1 (fr) Analogues de tofa, préparations de réduction de sébum contenant ledit type d'analogues et utilisation cosmétique et/ou thérapeutique dudit type d'analogues en tant que principe efficace pour réduire ou prévenir le sébum
WO2018099675A1 (fr) Utilisation de 2'-méthoxyflavones dans des préparations cosmétiques ou dermatologiques pour la prophylaxie et le traitement des peaux sensibles

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BEIERSDORF AG